The biotech industry is urged to prioritize drug resistance as a key scientific challenge. Addressing this issue could lead to significant advancements in treatment efficacy and patient outcomes.
We must treat drug resistance as a central scientific priority rather than an unavoidable complication.
Original title: “Tackling drug resistance must become biotech’s next frontier”